Progesterone Compounding Pharmacy: The 2026 Shortage, Peanut Allergy Gap, and What Patients Need Now

Introduction: Two Crises, One Solution

In mid-2026, patients and prescribers across the United States are confronting two problems simultaneously. The first is a nationwide progesterone shortage that has left pharmacy shelves empty of oral capsules, injectable formulations, and vaginal inserts. The second is quieter but no less serious: a permanent gap in the commercial market that leaves patients with peanut allergies without a safe, FDA-approved oral progesterone option.

The spark for the shortage came on February 12, 2026, when the FDA approved label changes to Prometrium (progesterone USP capsules in 100mg and 200mg strengths), removing the cardiovascular disease, breast cancer, and probable dementia risk statements from the boxed warning. That single regulatory decision reversed more than two decades of suppressed prescribing and triggered a demand surge that commercial manufacturers simply cannot meet fast enough.

The core message of this article is straightforward: a PCAB-accredited compounding pharmacy is not a workaround or a gray-market substitute. It is the legally authorized, medically necessary clinical safety net for both of these problems. This guidance is written for patients who cannot access or tolerate commercial progesterone, and for providers seeking a trusted pharmacy partner for their bioidentical hormone replacement therapy (BHRT) protocols. Among the pharmacies positioned to serve both needs is Nationwide Compounding Rx®, a PCAB-accredited 503A pharmacy that ships to 47 states plus Washington, D.C.

The 2026 Progesterone Shortage: What Happened and Why It Matters

For over twenty years, broad safety warnings on menopausal hormone therapy products discouraged both prescribers and patients from using progesterone. The FDA’s February 12, 2026 approval of revised Prometrium labeling changed that overnight. By stripping the cardiovascular, breast cancer, and dementia risk statements from the boxed warning, the agency effectively reintroduced hormone therapy as a mainstream option for menopausal women.

The market responded immediately. Estrogen patch prescriptions rose 19% following the label change, and progesterone prescriptions mirrored that spike. Because estrogen and progesterone are typically prescribed together to protect the uterine lining, the surge in one drove the surge in the other.

The scope of the resulting shortage is broad. The American Society of Health-System Pharmacists (ASHP) lists all three major progesterone formulations on its drug shortage database: oral capsules, injectable progesterone in oil, and vaginal inserts (Endometrin). This is not a single-product gap; it affects every route of delivery.

Commercial manufacturers cannot scale production quickly. Regulatory lead times, raw material supply chains, and finite manufacturing capacity all limit how fast supply can grow. Meanwhile, demand is enormous and rising. The global progesterone market was valued at approximately USD 5.52 billion in 2025 and is projected to reach USD 13.3 billion by 2032, growing at a compound annual rate of 13.4%.

The human impact is significant. Nearly 2 million women enter menopause each year in the United States. Fertility patients depend on vaginal inserts for luteal-phase support during IVF. Patients at risk of preterm birth rely on progesterone to reduce that risk. This is not a niche concern: more than 35% of treatment regimens for reproductive and endocrine conditions include progesterone.

The Legal Pathway: How Compounding Pharmacies Are Authorized to Fill the Gap

Under federal law, compounding pharmacies are explicitly permitted to replicate a commercially available drug when that drug appears on the official FDA drug shortage database. Progesterone’s presence on that list is precisely what authorizes compounders to step in.

In January 2025, the FDA released revised guidance clarifying that 503A compounding pharmacies can compound substances that are the active ingredient in an FDA-approved drug or that have a U.S. Pharmacopeia (USP) monograph. Progesterone qualifies under both criteria, placing it squarely within the bounds of legal compounding.

It helps to understand the two categories of compounding facilities. 503A pharmacies compound patient-specific prescriptions and are regulated by state Boards of Pharmacy. 503B outsourcing facilities are registered directly with the FDA and compound in bulk for healthcare providers. Both play important roles, but the patient-specific 503A model is what most individuals encounter when a prescriber orders a customized formulation.

Quality begins with sourcing. The FDA mandates that compounding pharmacists source raw progesterone powder exclusively from FDA-registered facilities meeting strict USP purity guidelines. The finished custom formulation is not individually FDA-approved, but the active ingredient must meet federal standards.

Ordinarily, 503A pharmacies may not compound a product that is essentially a copy of a commercially available medication unless a documented clinical difference exists. The active FDA shortage listing removes that barrier entirely for 2026. In this context, compounding is not a regulatory gray area; it is the system working exactly as designed.

The Peanut Allergy Gap: A Permanent Problem Commercial Manufacturers Have Not Solved

A fact many patients never learn until it becomes a problem: all currently FDA-approved oral micronized progesterone capsules contain peanut oil. As of May 2026, no peanut-oil-free oral micronized progesterone capsule has received FDA approval, making compounding the only oral option available to peanut-allergic patients.

Peanut oil is used as a solubilizing agent that enables micronized progesterone to be absorbed when taken orally. No commercial manufacturer has reformulated the product or sought approval for a peanut-oil-free alternative, so the ingredient remains standard across every branded and generic oral capsule.

For patients with documented peanut allergies, this is not a matter of preference. Taking Prometrium or any FDA-approved generic oral progesterone capsule carries a genuine risk of anaphylaxis, making this a patient safety issue.

Critically, this gap is permanent and not tied to the 2026 shortage. Even after supply normalizes, peanut-allergic patients will still have no FDA-approved oral option. This is where compounding becomes indispensable. A PCAB-accredited compounding pharmacy can formulate oral micronized progesterone capsules using alternative carrier oils, such as olive oil or sunflower oil, that are safe for peanut-allergic patients.

This is one of the clearest examples of a documented clinical difference that legally justifies compounding even outside of a shortage. The same logic extends to other excipients: patients sensitive to soy, gluten, artificial dyes, or lactose can have those ingredients removed through compounding. This kind of custom dosage and formulation flexibility is a defining advantage of the compounding model.

Understanding Compounded Progesterone: Formulations, Delivery Routes, and Clinical Use Cases

Compounded progesterone is a bioidentical hormone. Its molecular structure is chemically identical to the progesterone the body produces naturally, and it binds to progesterone receptors the same way endogenous progesterone does.

Precision matters when defining “bioidentical.” The term refers to molecular structure, not regulatory status. Compounded bioidentical progesterone is not FDA-approved as a finished product, but the raw progesterone USP ingredient it is made from is FDA-regulated and must meet USP purity standards.

Available Delivery Forms and Clinical Preferences

• Oral capsules (immediate-release and sustained-release): Available in custom strengths such as 50mg, 100mg, 150mg, 200mg, or higher. Sustained-release formulations slowly release progesterone over several hours. Taken before bed, oral progesterone converts to allopregnanolone, which interacts with GABA receptors in the brain to produce a calming effect that improves sleep architecture and reduces anxiety. Preferred for menopause HRT and sleep support.
• Transdermal creams and gels: Applied to the skin for systemic absorption. Preferred when patients cannot tolerate oral forms or when avoiding first-pass liver metabolism is a clinical goal. Transdermal progesterone carries different pharmacokinetics than oral formulations.
• Sublingual troches and drops: Dissolved under the tongue for faster absorption. Preferred for patients who cannot swallow capsules or who need rapid onset.
• Vaginal suppositories and creams: Deliver progesterone directly to uterine tissue. Critical for IVF and ART luteal-phase support (serving as a direct substitute for Endometrin during the shortage) and for patients where minimizing systemic exposure is a clinical priority.
• Injectable (intramuscular): Used in ART protocols and preterm birth prevention. Because injectable progesterone in oil is on the FDA shortage list, compounded injectable formulations are an essential alternative.

The ability to customize delivery form is a core clinical advantage of compounding that commercial manufacturers cannot match.

Key Clinical Indications for Compounded Progesterone

• Menopause and perimenopause HRT: The largest use case. Roughly 40% of menopause patients use bioidentical hormones, and nearly 2 million women enter menopause each year.
• IVF and ART luteal-phase support: Vaginal progesterone suppositories serve as a direct clinical substitute for Endometrin, currently on shortage. Compounding pharmacies are an essential supply chain for fertility clinics.
• Preterm birth prevention: Progesterone injections and vaginal progesterone are used to reduce preterm birth risk, and the injectable formulation is on the FDA shortage list.
• Secondary amenorrhea and menstrual regulation: Progesterone is used to induce withdrawal bleeding and regulate cycles.
• Gender-affirming hormone therapy: Progesterone is used in some feminizing hormone protocols.
• Sleep and anxiety support: The allopregnanolone and GABA mechanism makes oral sustained-release progesterone a relevant option for hormone-related sleep disturbances.

Approximately 55% of all progesterone prescriptions are directed toward reproductive health.

Quality, Safety, and Regulatory Standards in Compounded Progesterone

Transparency is essential here. An investigative study found that compounded progesterone capsules varied significantly in potency, with most containing roughly 80% of the prescribed dose and none meeting FDA potency requirements. Patients and providers should understand that this is a real, documented concern.

The key insight is that quality varies by pharmacy, not by compounding as a category. The differentiators are accreditation, compliance infrastructure, and sourcing practices.

PCAB accreditation is the gold standard for patient-facing quality assurance. The Pharmacy Compounding Accreditation Board sets standards based on USP guidelines and independently assesses pharmacies for safety and quality compliance.

Three USP standards govern how compounded medications are prepared:

• USP 795 covers non-sterile compounding.
• USP 797 covers sterile compounding.
• USP 800 covers hazardous drug handling.

A facility compliant with these standards eliminates cross-contamination risks. Raw material sourcing is equally important: the FDA requires compounding pharmacists to source raw progesterone powder from FDA-registered, USP-grade suppliers, and a PCAB-accredited pharmacy will document that chain of custody. Patients should always verify that a pharmacy uses pharmaceutical-grade ingredients and maintains rigorous sourcing documentation.

Professional guidance deserves honest treatment. Both ACOG and the Endocrine Society note that compounded BHRT should not be prescribed routinely when FDA-approved formulations exist, and that claims of superiority over FDA-approved therapy lack adequate evidence. Those positions, however, are premised on routine, preference-based use. They do not address shortage access or allergen exclusion, which are the specific clinical justifications this article covers.

A practical checklist for evaluating a compounding pharmacy: PCAB accreditation, USP 795/797/800 compliance, FDA-registered raw material sourcing, batch testing and certificates of conformance, and state licensure in the patient’s state.

How Nationwide Compounding Rx® Addresses Both the Shortage and the Peanut Allergy Gap

Nationwide Compounding Rx® is a PCAB-accredited 503A compounding pharmacy based in Scottsdale, Arizona, shipping to 47 states plus Washington, D.C.

Because progesterone is on the FDA drug shortage database, Nationwide Compounding Rx® is legally authorized to compound oral, vaginal, and injectable progesterone formulations for patients with valid prescriptions, filling the gap that commercial manufacturers cannot.

For peanut-allergic patients, the pharmacy can formulate oral micronized progesterone capsules without peanut oil, using alternative carrier bases that are safe for these patients. This formulation does not exist in the FDA-approved commercial market.

The pharmacy operates a USP 800-compliant facility, which eliminates cross-contamination risks, an especially important safeguard for patients with allergies. Available progesterone delivery forms include oral capsules (immediate-release and sustained-release), transdermal creams, sublingual troches, vaginal suppositories and creams, and injectable formulations.

With a one to two business day turnaround and nationwide shipping, the pharmacy is well suited to shortage-related urgency. Its staff brings 40 years of combined experience and a philosophy of individualized, patient-by-patient customization. Raw materials are sourced exclusively from FDA-inspected and cleared vendors, directly addressing the potency and quality concerns documented in the literature.

For transparency: the pharmacy serves 47 states plus Washington, D.C., but does not ship to Alabama, California, North Carolina, or South Carolina. Contact: 1-833-650-9836 or www.NationwideCompounding.com.

How to Get Compounded Progesterone: A Step-by-Step Guide for Patients and Providers

Compounded progesterone requires a valid prescription from a licensed prescriber and is not available direct-to-consumer.

The patient pathway:

1. Consult with a prescriber (OB-GYN, integrative medicine physician, nurse practitioner, or telehealth provider).
2. Discuss the shortage or peanut allergy situation and request a compounded formulation.
3. Have the prescriber send the prescription directly to a PCAB-accredited compounding pharmacy such as Nationwide Compounding Rx® via fax (480-699-5341) or another secure method.
4. The pharmacy compounds and ships within one to two business days.

The provider pathway: Establish a pharmacy partnership by contacting Nationwide Compounding Rx® directly at 480-499-8379 or 1-833-650-9836 to discuss formulary options, available strengths, and delivery forms for the patient population. Providers interested in a deeper collaboration can learn more about how to partner with a compounding pharmacy as a prescriber.

Telehealth integration: Patients who obtain a progesterone prescription via telehealth can have it sent directly to Nationwide Compounding Rx® for nationwide shipping to served states.

Prescription guidance for providers: Specify delivery form, strength, dosing frequency, and quantity. Critically, note any allergen exclusions (for example, “peanut-oil-free formulation required”) or shortage-related clinical justification. Providers can also fax prescriptions to the compounding pharmacy using the secure fax line at 480-699-5341.

Insurance and cost: Compounded progesterone is typically not covered by insurance and is paid out-of-pocket. Contact the pharmacy directly for pricing, which varies by formulation and strength.

Hours are Monday through Friday, 7:00am to 3:30pm MST.

Frequently Asked Questions About Compounded Progesterone in 2026

Is compounded progesterone legal? Yes. It is authorized under federal law, particularly during an active FDA-recognized drug shortage and when a documented clinical difference such as peanut allergy exists. The January 2025 FDA guidance explicitly permits compounding of substances with a USP monograph, which progesterone has.

Is compounded progesterone the same as Prometrium? The active molecule (progesterone USP) is chemically identical, but the finished compounded product is not FDA-approved as a finished dosage form. The raw ingredient must meet USP purity standards and come from FDA-registered suppliers.

Is compounded progesterone safe for patients with peanut allergies? When formulated without peanut oil by a PCAB-accredited, USP 800-compliant pharmacy using FDA-registered raw materials, yes. It is currently the only oral option available to peanut-allergic patients.

How long will the 2026 progesterone shortage last? As of mid-2026, all three major formulations remain on the ASHP shortage database. Resolution depends on manufacturer production capacity and demand normalization following the February 2026 label change.

What is the difference between a 503A and 503B pharmacy? 503A pharmacies compound patient-specific prescriptions and are regulated by state Boards of Pharmacy; 503B outsourcing facilities are FDA-registered and compound in bulk. Nationwide Compounding Rx® is a 503A pharmacy.

Can patients get compounded progesterone via telehealth? Yes. A telehealth prescriber can send a prescription directly to a licensed 503A compounding pharmacy for shipping to the patient’s state, provided that state is served.

What should patients look for in a compounding pharmacy? PCAB accreditation, USP 795/797/800 compliance, FDA-registered raw material sourcing, batch testing documentation, and licensure in the patient’s state. Reviewing a pharmacy’s compounding safety standards before placing an order is a practical first step.

Conclusion: Compounding Is Not a Last Resort; It Is the Right Clinical Tool for the Right Patient

In mid-2026, compounded progesterone from a PCAB-accredited pharmacy is not a compromise. It is the legally authorized, clinically appropriate solution to two concrete problems that commercial manufacturers cannot fix.

The first is the FDA-shortage-driven supply gap affecting oral, injectable, and vaginal progesterone across all commercial formulations. The second is the permanent peanut allergy gap that no FDA-approved oral progesterone product addresses.

The concerns raised by ACOG and the Endocrine Society are legitimate, but they apply to routine, preference-based use of compounded BHRT, not to shortage access or allergen exclusion. The difference between a safe, effective compounded progesterone and a subpotent one comes down to the pharmacy’s accreditation, compliance infrastructure, and sourcing standards. PCAB accreditation and USP 800 compliance are the patient’s quality assurance.

As the progesterone market grows toward USD 13.3 billion by 2032 and menopause awareness continues to expand, the role of compounding pharmacies as personalized medicine providers will only grow. The 2026 shortage and the peanut allergy gap make that role urgent now.

Ready to Get Compounded Progesterone? Contact Nationwide Compounding Rx® Today

For patients: Those with a progesterone prescription who cannot access commercial Prometrium because of the shortage, or who have a peanut allergy that makes all FDA-approved oral options unsafe, Nationwide Compounding Rx® can help.

For providers: OB-GYNs, integrative medicine physicians, nurse practitioners, and fertility specialists seeking a reliable compounding pharmacy partner for BHRT or ART protocols are encouraged to contact Nationwide Compounding Rx® to discuss formulary options and shipping capabilities. Prescriptions may be sent via fax to 480-699-5341, or providers may call the toll-free line to establish a partnership.

Contact details:

• Phone: 1-833-650-9836
• Local: 480-499-8379
• Fax: 480-699-5341
• Website: www.NationwideCompounding.com
• Address: 14000 N. Hayden Rd., Suite 104, Scottsdale, AZ 85260
• Hours: Monday through Friday, 7:00am to 3:30pm MST

With a one to two business day turnaround and nationwide shipping to 47 states plus Washington, D.C., backed by PCAB accreditation and USP 800 compliance, Nationwide Compounding Rx® delivers the quality assurance behind every compounded progesterone prescription.